Co-Authors
This is a "connection" page, showing publications co-authored by PAVEL SUMAZIN and ANDREW BADACHHAPE.
Connection Strength
0.247
-
A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma. J Hepatol. 2024 04; 80(4):610-621.
Score: 0.055
-
HepT1-derived murine models of high-risk hepatoblastoma display vascular invasion, metastasis, and circulating tumor cells. Biol Open. 2022 09 15; 11(9).
Score: 0.050
-
MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma. Nat Commun. 2022 06 28; 13(1):3728.
Score: 0.050
-
Author Correction: MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma. Sci Rep. 2021 Oct 01; 11(1):19916.
Score: 0.047
-
MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma. Sci Rep. 2021 02 03; 11(1):2967.
Score: 0.045